- Home
- PFL vs AUTL Comparison
PFL vs AUTL Comparison
Compare PFL & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFL
- AUTL
- Stock Information
- Founded
- PFL 2003
- AUTL 2014
- Country
- PFL United States
- AUTL United Kingdom
- Employees
- PFL N/A
- AUTL N/A
- Industry
- PFL Finance Companies
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFL Finance
- AUTL Health Care
- Exchange
- PFL Nasdaq
- AUTL Nasdaq
- Market Cap
- PFL 349.9M
- AUTL 359.3M
- IPO Year
- PFL N/A
- AUTL 2018
- Fundamental
- Price
- PFL $8.34
- AUTL $2.36
- Analyst Decision
- PFL
- AUTL Strong Buy
- Analyst Count
- PFL 0
- AUTL 5
- Target Price
- PFL N/A
- AUTL $9.32
- AVG Volume (30 Days)
- PFL 113.7K
- AUTL 2.5M
- Earning Date
- PFL 01-01-0001
- AUTL 05-08-2025
- Dividend Yield
- PFL 11.53%
- AUTL N/A
- EPS Growth
- PFL N/A
- AUTL N/A
- EPS
- PFL N/A
- AUTL N/A
- Revenue
- PFL N/A
- AUTL $9,011,000.00
- Revenue This Year
- PFL N/A
- AUTL $371.59
- Revenue Next Year
- PFL N/A
- AUTL $165.71
- P/E Ratio
- PFL N/A
- AUTL N/A
- Revenue Growth
- PFL N/A
- AUTL N/A
- 52 Week Low
- PFL $6.98
- AUTL $1.11
- 52 Week High
- PFL $8.62
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- PFL 55.70
- AUTL 81.27
- Support Level
- PFL $8.30
- AUTL $2.04
- Resistance Level
- PFL $8.40
- AUTL $1.79
- Average True Range (ATR)
- PFL 0.06
- AUTL 0.13
- MACD
- PFL 0.01
- AUTL 0.09
- Stochastic Oscillator
- PFL 76.00
- AUTL 94.66
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.